1. SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL. (12th June 2019) Authors: Nowakowski, G.; Willenbacher, W.; Greil, R.; Larsen, T.S.; Patel, K.; Jäger, U.; Manges, R.F.; Trümper, L.; Haioun, C.; Everaus, H.; Kalakonda, N.; Knoble, J.; de Nully Brown, P.; Jørgensen, J.M.; Cunningham, D.; Domper Rubio, N.; Casadebaig, M.; Manzke, O.; Munoz, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗